Defirox is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over). Defirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 µg/l). LIC is the preferred method of iron overload determination and should be used wherever available